Diabetic Retinopathy Market: By Drug Type (Aflibercept, Ranibizumab, Corticosteroids, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (HOSPITAL PHARMACIES, RETAIL PHARMACIES, ONLINE PHARMACIES), and Geography      

Purchase Option

$ 4400
$ 6600
$ 8900

Diabetic Retinopathy Market size was valued at USD 6.24 billion in 2023 and is poised to grow at a CAGR of 7.1% from 2024-2030. Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects people with diabetes for a number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation of diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy market is not properly treated, can progressively become more serious and seriously affect vision which may lead to blindness. Diabetic retinopathy can be treated by various methods depending on the stage of the disease. Diabetic retinopathy is one of the major causes of blindness in the adult population in America.

As per, the World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population had diabetic retinopathy. An increase in focus on Asia-Pacific and LAMEA regions by various vendors is expected to boost the diabetic retinopathy market growth of the market According to the World Bank, in 2015,10.4% of rate of prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships, and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.

Global Diabetic Retinopathy Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.1%

Largest Market

North America

Fastest Growing Market

Europe
Diabetic Retinopathy Market Dynamics

Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation (WHO), 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure up-gradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the diabetic retinopathy market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of diabetic retinopathy market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Diabetic Retinopathy Market Segmentation

By Type
  • Proliferative Diabetic Retinopathy
  • Diabetic Macular Edema
By Drug Class
  • Corticosteroids
  • Anti-VEGF (vascular endothelial growth factor)
By Distribution Channel
  • Ophthalmic Clinics
  • Hospital Pharmacies
  • Retail pharmacies

Frequently Asked Questions

The diabetic retinopathy market size was valued at USD 6.24 billion in 2023

Abbott Laboratories (U.S.), Alimera Sciences (U.S.), Allergan plc (Ireland.), Ampio Pharmaceuticals. (U.S.), Bayer AG (Germany), F. Hoffmann-La Roche (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Valeant (Canada)

Europe is the fastest-growing region in the diabetic retinopathy market

1. Executive Summary
2. Global Diabetic Retinopathy Market Introduction
2.1. Global Diabetic Retinopathy Market - Taxonomy
2.2. Global Diabetic Retinopathy Market - Definitions
2.2.1. Drug Type
2.2.2. Route of Administration
2.2.3. Distribution Channel
3. Global Diabetic Retinopathy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Diabetic Retinopathy Treatment Market Dynamic Factors - Impact Analysis
3.6. Global Diabetic Retinopathy Treatment Market Competition Landscape
4. Global Diabetic Retinopathy Market, By Drug Type, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.1. Aflibercept
4.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Ranibizumab
4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Corticosteroids
4.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Others
4.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
4.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
5. Global Diabetic Retinopathy Treatment Market Forecast, By Route of Administration, 2019 - 2023 and Forecast, 2021 2027 (Revenue, USD Mn)
5.1. Oral
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Parenteral
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Others
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Diabetic Retinopathy Treatment Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.1. HOSPITAL PHARMACIES
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. RETAIL PHARMACIES
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. ONLINE PHARMACIES
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Diabetic Retinopathy Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel and Region, 2024-2030
8. North America Diabetic Retinopathy Treatment MarketAnalysis,2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
8.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
8.1.1. Aflibercept
8.1.2. Ranibizumab
8.1.3. Corticosteroids
8.1.4. Others
8.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Oral
8.2.2. Parenteral
8.2.3. Others
8.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.3.1. HOSPITAL PHARMACIES
8.3.2. RETAIL PHARMACIES
8.3.3. ONLINE PHARMACIES
8.4. Country Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.4.1. USA
8.4.2. Canada
8.5. North America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030
8.6. North America Diabetic Retinopathy Treatment Market Dynamics Trends
9. Europe Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
9.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Aflibercept
9.1.2. Ranibizumab
9.1.3. Corticosteroids
9.1.4. Others
9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.2.3. Others
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. HOSPITAL PHARMACIES
9.3.2. RETAIL PHARMACIES
9.3.3. ONLINE PHARMACIES
9.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. Germany
9.4.2. UK
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Russia
9.4.7. Poland
9.4.8. Rest of Europe
9.5. Europe Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By  Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030
9.6. Europe Diabetic Retinopathy Treatment Market Dynamics Trends
10. Asia-Pacific Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
10.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Aflibercept
10.1.2. Ranibizumab
10.1.3. Corticosteroids
10.1.4. Others
10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.2.3. Others
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. HOSPITAL PHARMACIES
10.3.2. RETAIL PHARMACIES
10.3.3. ONLINE PHARMACIES
10.4. Country Analysis2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. ASEAN
10.4.5. Australia & New Zealand
10.4.6. Rest of Asia-Pacific
10.5. Asia-Pacific Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By  Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030
10.6. Asia-Pacific Diabetic Retinopathy Treatment Market Dynamics Trends
11. Latin America Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
11.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Aflibercept
11.1.2. Ranibizumab
11.1.3. Corticosteroids
11.1.4. Others
11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.2.3. Others
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. HOSPITAL PHARMACIES
11.3.2. RETAIL PHARMACIES
11.3.3. ONLINE PHARMACIES
11.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Argentina
11.4.4. Rest of Latin America
11.5. Latin America Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030
11.6. Latin America Diabetic Retinopathy Treatment Market Dynamics Trends
12. Middle East and Africa Diabetic Retinopathy Treatment Market Analysis, 2019 - 2023 and Forecast, 2024-2030 (Revenue, USD Mn)
12.1. By Drug Type Analysis 2019 - 2023 and Forecast 2024-2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Aflibercept
12.1.2. Ranibizumab
12.1.3. Corticosteroids
12.1.4. Others
12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.2.3. Others
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. HOSPITAL PHARMACIES
12.3.2. RETAIL PHARMACIES
12.3.3. ONLINE PHARMACIES
12.4. Country Analysis 2019 - 2023 and Forecast 2024-2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Gulf Cooperation Council (GCC) Countries
12.4.2. Israel
12.4.3. South Africa
12.4.4. Rest of MEA
12.5. MEA Diabetic Retinopathy Treatment Market - Opportunity Analysis Index, By  Drug Type, Route of Administration, Distribution Channel, and Country, 2024-2030
12.6. MEA Diabetic Retinopathy Treatment Market Dynamics Trends
13. Global Diabetic Retinopathy Treatment - Pipeline Drug Analysis
13.1. Global Diabetic Retinopathy Treatment Disease Epidemiology
13.2 Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment
13.3. Global Diabetic Retinopathy Treatment, Pipeline Drugs Assessment - Sponsors/Companies
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Regeneron Pharmaceuticals
14.2.2. Novartis AG
14.2.3. Genentech
14.2.4. Novartis AG
14.2.5. Bayer AG
14.2.6. Oxurion
14.2.7. OccuRx
14.2.8. AptaBio Therapeutics
14.2.9. Kodiak Sciences
14.2.10. RemeGen
14.2.11. F. Hoffman-La-Roche AG.
14.2.12. Grifols S.A.
15. Research Methodology
16. Key Assumptions and Acronymsc
  • Abbott Laboratories (U.S.)
  • Alimera Sciences (U.S.)
  • Allergan plc (Ireland.)
  • Ampio Pharmaceuticals. (U.S.)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Regeneron Pharmaceuticals Inc. (U.S.)
  • Valeant (Canada)

Adjacent Markets